[1] |
Jemal A,Siegel R,Ward E,et al.Cancer statistics,2009[J].CA Cancer J Clin,2009,59(4):225-249.
|
[2] |
Cui Z,Yin Z,Li X,et al.Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer:a meta-analysis[J].BMC Cancer,2012,12:71-82.
|
[3] |
Butkiewicz D,Rusin M,Sikora B,et al.An association between DNA repair gene polymorphisms and survival in patients with resected non-small cell lung cancer[J].Mol Biol Rep,2011,38(8):5231-5241.
|
[4] |
Kim M,Kang HG,Lee SY,et al.Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non-small-cell lung cancer[J].Cancer Sci,2010,101(11):2436-2442.
|
[5] |
Wu W,Li H,Wang H,et al.Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients[J].PLoS One,2012,7(3):e33200.
|
[6] |
Sun Z,Chen J,Aakre J,et al.Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients[J].Ann Oncol,2010,21(10):2011-2016.
|
[7] |
Brundage MD,Davies D,Mackillop WJ.Prognostic factors in non-small cell lung cancer:a decade of progress[J].Chest,2002,3(122):1037-1057.
|
[8] |
Hoeijmakers JH.Genome maintenance mechanisms for preventing cancer[J].Nature,2001,411(6835):366-374.
|
[9] |
高坚瑞.DNA损伤修复能力与肺癌易感性研究[J].中国公共卫生,2000,16(5):478-479.
|
[10] |
唐春兰,杨和平,周向东.DNA损伤修复与肺癌顺铂耐药机制的研究进展[J].中国肺癌杂志,2011,14(12):960-964.
|
[11] |
吕嘉春,吴中亮,施侣元,等.核苷酸切除修复基因表达低下与肺癌的关系[J].中国公共卫生,2003,19(7):780-782.
|
[12] |
Yin Z,Zhou B,He Q,et al.Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma[J].BMC Cancer,2009,9(12):439-445.
|
[13] |
Madhusudan S,Middleton MR.The emerging role of DNA repair proteins as predictive,prognostic and therapeutic targets in cancer[J].Cancer Treat Rev,2005,31(8):603-617.
|
[14] |
Matullo G,Dunning AM,Guarrera S,et al.DNA repair polymorphisms and cancer risk in non-smokers in a cohort study[J].Carcinogenesis,2006,27(5):997-1007.
|
[15] |
Vilmar A,Sorensen JB.Excision repair cross-complementation group 1(ERCC1)in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin:a review of current literature[J].Lung Cancer,2009,64(2):131-139.
|
[16] |
Taillade L,Penault-Llorca F,Boulet T,et al.Immunohistochemical expression of biomarkers:a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer[J].Ann Oncol,2007,18(6):1043-1050.
|
[17] |
Takenaka T,Yoshino I,Kouso H,et al.Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer[J].Int J Cancer,2007,121(4):895-900.
|
[18] |
Ding Z,Zhang J,Shao J.ERCC1 expression as a predictor of survival after operation in stage I non-small cell lung cancer patients[J].Zhongguo Fei Ai Za Zhi,2010,13(5):522-525.
|
[19] |
Olaussen KA,Dunant A,Fouret P,et al.DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J].N Engl J Med,2006,335(10):983-991.
|
[20] |
Zheng Z,Chen T,Li X,et al.DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer[J].N Engl J Med,2007,356(8):800-808.
|
[21] |
Takenaka T,Yano T,Kiyohara C,et al.Effects of excision repair cross-complementation group 1(ERCC1)single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients[J].Lung Cancer,2010,67(1):101-107.
|
[22] |
Isla D,Sarries C,Rosell R,et al.Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer[J].Ann Oncol,2004,15(8):1194-1203.
|
[23] |
Ren S,Zhou S,Wu F,et al.Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy[J].Lung Cancer,2012,75(1):102-109.
|
[24] |
Krawczyk P,Wojas-Krawczyk K,Mlak R,et al.Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer-a pilot study[J].Folia Histochem Cytobiol,2012,50(1):80-86.
|
[25] |
de Las PR,Sanchez-Ronco M,Alberola V,et al.Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients[J].Ann Oncol,2006,17(4):668-675.
|
[26] |
Yin M,Yan J,Voutsina A,et al.No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer:a meta-analysis[J].Lung Cancer,2011,72(3):370-377.
|
[27] |
Gurubhagavatula S,Liu G,Park S,et al.XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy[J].J Clin Oncol,2004,22(13):2594-2601.
|
[28] |
Booton R,Ward T,Heighway J,et al.Xeroderma pigmentosum group D haplotype predicts for response,survival,and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer[J].Cancer,2006,106(11):2421-2427.
|
[29] |
Tibaldi C,Giovannetti E,Vasile E,et al.Correlation of CDA,ERCC1,and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients[J].Clin Cancer Res,2008,14(6):1797-803.
|
[30] |
Wu X,Zhao H,Wei Q,et al.XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity[J].Carcinogenesis,2003,24(3):505-509.
|
[31] |
Feng J,Sun X,Sun N,et al.XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer[J].Acta Biochim Biophys Sin(Shanghai),2009,41(5):429-435.
|
[32] |
Bernardes DJB,Bjoras M,Coin F,et al.Dissection of the molecular defects caused by pathogenic mutations in the DNA repair factor XPC[J].Mol Cell Biol,2008,28(23):7225-7235.
|
[33] |
洪晓华.XPA、XPC和XRCC1基因多态性与非小细胞肺癌铂类化疗患者预后的关系[J].武汉:华中科技大学硕士学位论文,2011.
|
[34] |
Kiyohara C,Takayama K,Nakanishi Y.Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk:a meta-analysis[J].Lung Cancer,2006,54(3):267-283.
|
[35] |
Schneider J,Classen V,Helmig S.XRCC1 polymorphism and lung cancer risk[J].Expert Rev Mol Diagn,2008,8(6):761-780.
|
[36] |
Yao CY,Huang XE,Li C,et al.Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers[J].Asian Pac J Cancer Prev,2009,10(5):859-864.
|
[37] |
Lockett KL,Hall MC,Xu J,et al.The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function[J].Cancer Res,2004,64(17):6344-6348.
|
[38] |
Zhang X,Miao X,Liang G,et al.Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer[J].Cancer Res,2005,65(3):722-726.
|
[39] |
Sanyal S,De Verdier PJ,Steineck G,et al.Polymorphisms in XPD,XPC and the risk of death in patients with urinary bladder neoplasms[J].Acta Oncol,2007,46(1):31-41.
|
[40] |
Butkiewicz D,Rusin M,Enewold L,et al.Genetic polymorphisms in DNA repair genes and risk of lung cancer[J].Carcinogenesis,2001,22(4):593-597.
|
[41] |
Matullo G,Palli D,Peluso M,et al.XRCC1,XRCC3,XPD gene poly-morphisms,smoking and(32)P-DNA adducts in a sample of healthy subjects[J].Carcinogenesis,2001,22(9):1437-1445.
|
[42] |
Au WW,Salama SA,Sierra-Torres CH.Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays[J].Environ Health Perspect,2003,111(15):1843-1850.
|
[43] |
Improta G,Sgambato A,Bianchino G,et al.Polymorphisms of the DNA repair genes XRCC1 and XRCC3 and risk of lung and colorectal cancer:a case-control study in a Southern Italian population[J].Anticancer Res,2008,28(5B):2941-2946.
|
[44] |
Hsu NY,Wang HC,Wang CH,et al.Lung cancer susceptibility and genetic polymorphism of DNA repair gene XRCC4 in Taiwan[J].Cancer Biomark,2009,5(4):159-165.
|
[45] |
Shao N,Jiang WY,Qiao D,et al.An updated meta-analysis of XRCC4 polymorphisms and cancer risk based on 31 case-control studies[J].Cancer Biomark,2012,12(1):37-47.
|
[46] |
Xu JL,Hu LM,Huang MD,et al.Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese[J].Asian Pac J Cancer Prev,2012,13(3):851-856.
|
[47] |
Rosell R,Skrzypski M,Jassem E,et al.BRCA1:a novel prognostic factor in resected non-small-cell lung cancer[J].PLoS One,2007,11(2):e1129.
|
[48] |
Taron M,Rosell R,Felip E,et al.BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer[J].Hum Mol Genet,2004,20(13):2443-2449.
|
[49] |
Hsu HS,Wen CK,Tang YA,et al.Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer[J].Clin Cancer Res,2005,15(11):5410-5416.
|
[50] |
Cheng H,Sun N,Sun X,et al.Polymorphisms in hMSH2 and hMLH1 and response to platinum-based chemotherapy in advanced non-small-cell lung cancer patients[J].Acta Biochim Biophys Sin(Shanghai),2010,42(5):311-317.
|